Biocrossroads News Archives - Page 4 of 6 - The Central Indiana Corporate Partnership

2021 Indiana Life Sciences Summit features global life sciences and healthcare leaders

Raquel Bahamonde2021-08-04T08:38:13-04:00August 4, 2021|

INDIANAPOLIS (August 4, 2021) – BioCrossroads 2021 Virtual Indiana Life Sciences Summit will feature global life sciences and healthcare thought leaders who will discuss how inclusion and collaboration have changed in the two industries over the last year. The conference is Wednesday, Oct. 13 and the live stream kicks off at 10:00 a.m. Life sciences and healthcare industry speakers include: Dr. Freda Lewis-Hall, former chief patient officer and executive vice president of Pfizer, Inc./consultant at PhRMA Dr. Virginia A. Caine, director, Marion County Public Health Department Dennis Murphy, president and CEO, IU Health Dr. Peter Kim, director, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health Dr. Anthony Philippakis, chief data scientist, Broad Institute Dr. Richard DiMarchi, distinguished professor of Chemistry and Gill Chair in Biomolecular Sciences, Indiana University Keynotes will be [...]

Indiana’s life sciences companies accessed more than $9 billion to grow innovation in 2020 BioCrossroads report details funding sources, deals, investors

Raquel Bahamonde2021-05-05T06:36:06-04:00April 12, 2021|

INDIANAPOLIS (April 12, 2021) -- In 2020, Indiana’s life sciences companies accessed over $9 billion in capital to grow and support innovation. The funding comes from a variety of sources including Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards, venture capital, initial public offerings and related public offerings, and mergers and acquisitions. BioCrossroads today issued their annual report, Indiana Life Sciences Capital 2020, which provides details on the funding events throughout the year. The $9 billion includes: $12.6 million SBIR awarded to 21 companies. $262 million in venture capital invested in 44 companies. $141.8 million accessed through public markets by three companies. $8.6 billion+ spent to acquire innovation, representing nine transactions. The market capitalization for Indiana’s public life sciences companies as of Dec. 31, 2020 was $297.6 billion and includes Eli Lilly and Company, Anthem, Zimmer [...]

Indiana’s life sciences industry breaks yearly records in two key categories – exports and venture capital

Raquel Bahamonde2021-04-21T11:21:42-04:00March 25, 2021|

INDIANAPOLIS, (March 25, 2021) -- While COVID-19 continues to make the headlines, Indiana’s life sciences industry not only combatted the pandemic with testing, treatments, clinical trials, and vaccine manufacturing but remained committed to innovating and investing throughout 2020. New data provided to BioCrossroads by the Indiana Business Research Center (IBRC) at the Indiana University Kelley School of Business shows a thriving and growing sector. One of the most notable milestones: Indiana is the second highest exporter of life sciences products in the U.S. and has been for more than a decade. In 2020, more than $11.4 billion of products were exported from the state, representing more than $192,000 of output per worker, the highest amount ever recorded. In addition, Indiana life sciences start-ups garnered a record level of venture capital investment with more than $262 million committed to 44 companies, [...]

BioCrossroads report underscores importance of strong tech transfer programs at Indiana’s research universities

Raquel Bahamonde2021-04-05T16:47:42-04:00November 19, 2020|

INDIANAPOLIS, (Nov. 19, 2020) -- BioCrossroads today released a new report, Tech Transfer in Indiana: An Overview for the Life Sciences Industry, a comprehensive resource highlighting the technology transfer processes and approaches used by Indiana University, Purdue University and the University of Notre Dame to facilitate commercialization of research-driven discoveries and innovations. The report also discusses the role of incubators and graduation facilities at research universities, which are increasing in number and importance. “With our three research institutions and thousands of research faculty, Indiana has critical assets necessary to drive innovation. University labs and facilities are especially important for life sciences R&D that require unique space and equipment required to perform complex research,” said Patricia Martin, president and CEO, BioCrossroads. In addition to developing breakthroughs in medical treatments and therapies, Indiana’s three R11 research institutions also generate a substantial amount of [...]

Richard M. Fairbanks Foundation grants BioCrossroads funding to advance collaborative and educational life sciences initiatives

Raquel Bahamonde2021-04-05T16:47:42-04:00October 29, 2020|

INDIANAPOLIS (Oct. 29, 2020) -- BioCrossroads announced today that the Richard M. Fairbanks Foundation has made a grant of $1.35 million to the organization to continue to advance the strength and opportunities of several collaborative and educational initiatives within Indiana’s life sciences sector. The Fairbanks Foundation is an Indianapolis-based, independent, private foundation focused on the education, health and the vitality of the Indianapolis community. “The life sciences sector is a key driver of Indiana’s economy, accounting for 20% of the state’s GDP. BioCrossroads plays a critical role helping to create an environment in which this sector can flourish,” said Claire Fiddian-Green, president and CEO of the Richard M. Fairbanks Foundation. “We are pleased to provide continued support for the organization and its key initiatives.” The two-year grant enables BioCrossroads to continue to advance Indiana’s vitality in the life sciences via [...]

Indiana’s premier drug development and manufacturing sector adds another company to its ecosystem

Raquel Bahamonde2021-04-05T16:47:43-04:00October 15, 2020|

INCOG BioPharma Services, Inc. announced plans to build new facility in Fishers, Ind., add 150 new jobs INDIANAPOLIS (Oct. 15, 2020) - Indiana is one of the premier contract drug development and manufacturing centers in the United States. These pharmaceutical contract service providers support the growing outsourcing needs of both large pharmaceutical and smaller biotechnology companies. Nearly 40 contract research and manufacturing organizations employ more than 7,000 workers throughout the state. Companies like Covance Central Labs (Indianapolis), Catalent Biologics (Bloomington) and B2S Life Sciences (Franklin) provide pre-clinical testing, toxicology, product manufacturing and other support to pharmaceutical companies worldwide. Pharmaceutical and biotechnology companies would not be able to discover, develop and distribute their products without these important partners. This week, INCOG BioPharma announced that they are forming a new biopharmaceutical manufacturing company in Fishers, Ind. Formed by an experienced management team, [...]

Developer of Echocardiography Dr. Harvey Feigenbaum honored as BioCrossroads 2020 Life Sciences Champion of the Year

Raquel Bahamonde2021-04-05T16:47:43-04:00October 7, 2020|

INDIANAPOLIS (Oct. 7, 2020) — BioCrossroads’ Board of Directors named esteemed “Father of Echocardiography” (Echo) Dr. Harvey Feigenbaum, as the recipient of the 2020 August M. Watanabe Life Sciences Champion of the Year Award. The prestigious honor, named in tribute to BioCrossroads’ late Chairman August Watanabe, was given to Dr. Feigenbaum at today’s Indiana Life Sciences Summit for his unprecedented impact on cardiac health in Indiana and around the world. Dr. Feigenbaum is recognized for pioneering the Echo, the most widely used cardiac imaging technique in the world. Dr. Feigenbaum has made numerous contributions to the medical profession that include developing the world’s first practical, long lasting use of echocardiography, the use of ultrasound to examine the heart, in 1965. He fought and overcame many years of skepticism by training many early world-wide pioneers in echocardiography and the first cardiac sonographer. [...]

BioCrossroads publishes directory of Indiana health and life sciences data organizations

Raquel Bahamonde2021-04-05T16:47:43-04:00July 7, 2020|

INDIANAPOLIS (July 7, 2020) – Indiana’s industry, government, health systems, academia, and digital health startups have tremendous data and technology resources which are driving transformative healthcare and life sciences work locally and globally. To capture all of those assets in a one-stop spot, BioCrossroads today published its Book of Data and Organizations, a directory of Indiana enterprises in the health-data intersection. The directory includes snapshots of ten organizations who control data assets – data sets, data talent, and/or data technology. The organization profiles answer: Who has what data? How can this data be accessed? Where does the data analysis talent reside? What data technologies and capabilities exist? What are the key projects currently in process? What are the future projects and opportunities for engagement? “Indiana has valuable and innovative life sciences and healthcare data initiatives and organizations that we’re highlighting through this [...]

Indiana’s life sciences industry ranks among the top 10 in national report

Raquel Bahamonde2021-04-05T16:47:43-04:00June 9, 2020|

INDIANAPOLIS (June 9, 2020) – Seven Indiana cities are recognized for their national life science strengths, according to Biotechnology Industry Organization (BIO) and TEConomy Partners’ biennial survey of the U.S. life sciences industry released today. Bloomington, Evansville, Indianapolis, Lafayette, Michigan City, South Bend and Terre Haute are identified in the report as having significant life sciences activity. Lafayette is one of only seven cities in the U.S to have employment specializations in four of the five industry subsectors. Bloomington and Indianapolis have employment specializations in three of the five industry subsectors (two of only 23 cities in the U.S. with that distinction). The report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities, measures growth in the bioscience sector (Agricultural Feedstock and Chemicals, Drugs and Pharmaceuticals, Medical Devices and Research, Testing and Medical Laboratories and Bioscience-related Distribution) from [...]

$9.1 billion of capital accessed by Indiana life sciences companies in 2019

Raquel Bahamonde2021-04-05T16:47:43-04:00April 22, 2020|

INDIANAPOLIS (April 22, 2020) – BioCrossroads today released a new report which details the sources and amounts of capital supporting Indiana’s life sciences sector in 2019. An impressive $9.1 billion in capital was accessed by Indiana life sciences companies in 2019: $8.6 million Small Business Innovation Research (SBIR) grants were awarded to 21 companies; $177 million in venture capital was invested in 37 companies; $178.7 million was accessed through public markets by two companies; and, More than $8.7 billion was spent to acquire innovation, representing eight transactions. Indiana’s life sciences companies raised over $360 million, excluding the significant funding represented by mergers and acquisitions, in 2019. These funds support innovation to discover and develop new therapies for diseases. “Having access to multiple capital investment vehicles fuels Indiana’s diverse and vibrant life sciences industry, which adds to the strength of the [...]

MAIN MENU

IMPORTANT LINKS

INITIATIVES